Periodic Reporting for period 3 - CureGLIO (Clinical validation of GLIX1: a small molecule that targets epigenetic changes in cancer cells to treat glioblastoma multiforme (GBM), the highest global unmet need in oncology.)
Periodo di rendicontazione: 2025-01-01 al 2025-12-31
CureGLIO is an EIC Accelerator–funded project dedicated to advancing GLIX1, a novel small-molecule therapeutic targeting epigenetic regulation and DNA-damage response mechanisms, for the treatment of glioblastoma multiforme (GBM) — one of the most aggressive and fatal cancers, characterized by poor survival outcomes and very limited effective treatment options. The project addresses a major unmet medical need in oncology by focusing on a differentiated mechanism of action designed to modulate tumor cell biology at the epigenetic level. At project start, GLIX1 was in advanced preclinical development, and the program has since concentrated on the high-risk translational step of moving from laboratory research into clinical readiness. This has included completion of GLP-compliant pharmacokinetic and repeated-dose toxicology studies in two species, generation of the full non-clinical safety package required for regulatory submission, and establishment of clinical dose rationale and safety margins. In parallel, GMP manufacturing of clinical drug substance and drug product has been achieved, with quality release and long-term stability supporting clinical supply. Regulatory progress has been marked by successful preparation and clearance of a U.S. Investigational New Drug (IND) application, along with engagement of leading academic clinical centers for execution of a first-in-human Phase 1/2 study. A companion diagnostic strategy was initially explored but discontinued after analytical verification demonstrated that the proposed biomarker approach was not technically viable, enabling resources to be redirected toward direct clinical development without compromising the core objective. Overall, the project’s purpose is to de-risk GLIX1 and enable first-in-human clinical testing, while simultaneously strengthening intellectual property protection, commercialization planning, regulatory positioning, and project governance to support long-term scientific, medical, and economic impact.
The project carried out a comprehensive set of scientific and technical activities to transition GLIX1 from advanced preclinical development to full clinical readiness. A complete non-clinical development program was executed, including pharmacokinetic characterization and GLP-compliant repeated-dose toxicology studies in rat and dog, supported by validated bioanalytical methods and toxicokinetic assessments. These studies defined systemic exposure, bioavailability, safety margins, and dose rationale, generating the regulatory-grade data package required for human entry. All non-clinical reports were finalized, quality assured, and formally accepted, establishing the safety foundation for clinical testing.
On the regulatory and translational side, the project prepared the full clinical documentation set, including the Investigator’s Brochure, clinical protocol, and integrated non-clinical summaries, culminating in successful submission and clearance of a U.S. FDA Investigational New Drug (IND) application. This outcome represents formal regulatory authorization to initiate first-in-human testing. In parallel, GMP manufacturing of clinical drug substance and drug product was completed, with formulation into oral capsules, QA/QP release, and long-term stability data supporting a shelf life of up to two years. Clinical material is therefore available and technically ready for trial use. Clinical site agreements and informed consent documentation were finalized, enabling operational readiness for trial initiation once enrollment begins.
A companion diagnostic (CDx) strategy was scientifically evaluated through prototype kit development and extensive analytical and biological verification studies, including biomarker correlation analyses across cell models and transcriptomic datasets. The outcome demonstrated that the investigated biomarker approach did not provide a technically or clinically actionable correlation with GLIX1 response. As a result, CDx development was discontinued based on validated negative findings, preventing inefficient downstream investment and allowing full focus on therapeutic development without impacting the core clinical objective.
Overall, the main technical achievements are: completion of the full non-clinical safety and pharmacokinetic package; establishment of clinical dose rationale; successful GMP manufacture and quality release of clinical material; regulatory clearance to proceed to human trials; and validated resolution of the CDx feasibility question. Together, these outcomes move GLIX1 across the critical translational threshold from preclinical research into regulatory and operational readiness for first-in-human clinical evaluation.
On the regulatory and translational side, the project prepared the full clinical documentation set, including the Investigator’s Brochure, clinical protocol, and integrated non-clinical summaries, culminating in successful submission and clearance of a U.S. FDA Investigational New Drug (IND) application. This outcome represents formal regulatory authorization to initiate first-in-human testing. In parallel, GMP manufacturing of clinical drug substance and drug product was completed, with formulation into oral capsules, QA/QP release, and long-term stability data supporting a shelf life of up to two years. Clinical material is therefore available and technically ready for trial use. Clinical site agreements and informed consent documentation were finalized, enabling operational readiness for trial initiation once enrollment begins.
A companion diagnostic (CDx) strategy was scientifically evaluated through prototype kit development and extensive analytical and biological verification studies, including biomarker correlation analyses across cell models and transcriptomic datasets. The outcome demonstrated that the investigated biomarker approach did not provide a technically or clinically actionable correlation with GLIX1 response. As a result, CDx development was discontinued based on validated negative findings, preventing inefficient downstream investment and allowing full focus on therapeutic development without impacting the core clinical objective.
Overall, the main technical achievements are: completion of the full non-clinical safety and pharmacokinetic package; establishment of clinical dose rationale; successful GMP manufacture and quality release of clinical material; regulatory clearance to proceed to human trials; and validated resolution of the CDx feasibility question. Together, these outcomes move GLIX1 across the critical translational threshold from preclinical research into regulatory and operational readiness for first-in-human clinical evaluation.
The project generated a comprehensive set of technical and translational results that position GLIX1 at the threshold of clinical validation. A full regulatory-grade non-clinical package was completed, including GLP-compliant pharmacokinetic and repeated-dose toxicology studies in two species, establishing systemic exposure, safety margins, and clinical dose rationale. In parallel, GMP manufacturing and quality release of clinical drug substance and drug product were achieved, with stability data supporting clinical supply readiness. Regulatory progress culminated in FDA clearance of the IND application, providing formal authorization for first-in-human testing. Scientific evaluation of the companion diagnostic concept delivered validated negative results, demonstrating lack of a technically viable biomarker and enabling strategic focus on therapeutic development. These outcomes collectively enable transition from preclinical research to clinical execution. The potential impacts include advancing a novel epigenetic oncology mechanism into human testing in glioblastoma, increasing asset maturity and partnering value, strengthening industrial and regulatory capabilities, and creating a pathway toward new treatment options for a disease with major unmet need. To ensure further uptake and success, key needs include successful clinical demonstration, continued access to finance, strong commercialization and partnering pathways, ongoing IPR support, and alignment with supportive regulatory frameworks and international clinical expansion.